Drug Application
Comparison on effects of irbesartan hydrochlorothiazide versus amlodipine besylate on elderly hypertension
Wang Lei, Wang Yi
Published 2022-03-10
Cite as Chin J Pract Med, 2022, 49(5): 84-87. DOI: 10.3760/cma.j.cn115689-20211201-04360
Abstract
ObjectiveTo compare the clinical effects of irbesartan hydrochlorothiazide and amlodipine besylate tablets in the treatment of elderly hypertension.
MethodsA total of 118 elderly hypertensive patients admitted to Pingmei Shenma Group General Hospital from December 2019 to June 2021 were selected and divided into irbesartan hydrochlorothiazide group (57 cases) and amlodipine group (61 cases). The irbesartan hydrochlorothiazide group was treated with irbesartan hydrochlorothiazide, and the amlodipine group was treated with amlodipine besylate. The clinical efficacy, blood pressure changes, blood pressure variability, hemorheological indexes including whole blood high-shear viscosity (HBV), whole blood low-shear viscosity (LBV), plasma viscosity (PV), and adverse reactions were compared between the two groups.
ResultsThe clinical efficacy of irbesartan hydrochlorothiazide group was 94.74%(54/57), which was higher than 81.96%(50/61) of amlodipine group (P<0.05). Three months of treatment, the mean systolic blood pressure (SBP) and mean diastolic blood pressure (DBP) within 24 hours, the lowest value of SBP and DBP during nighttime sleep, the mean SBP and mean DBP within 2 hours in the morning, and the variability of SBP and DBP within 24 hours in the two groups were lower than those before treatment (all P<0.05). The variability of SBP and DBP within 24 hours in the amlodipine group was lower than that in the irbesartan hydrochlorothiazide group (all P<0.05). Three months of treatment, HBV, LBV and PV in the two groups were lower than those before treatment (all P<0.05), and these indexes in the irbesartan hydrochlorothiazide group were lower than those in the amlodipine group after treatment (t=0.017, 0.016, 0.025; P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.048, P>0.05).
ConclusionsIrbesartan-hydrochlorothiazide and amlodipine besylate are effective in the treatment of elderly hypertension. Amlodipine besylate has a relatively stable curative effect, and irbesartan hydrochlorothiazide has a better effect on improving blood status.
Key words:
Hypertension; Irbesartan hydrochlorothiazide; Amlodipine besylate; Hemorheology
Contributor Information
Wang Lei
Department of Cadiology, Pingmei Shenma Group General Hospital, Pingdingshan 467000, China
Wang Yi
Department of Cadiology, Pingmei Shenma Group General Hospital, Pingdingshan 467000, China
